Table 4.

Correlation of CCR7 expression with clinicopathological features in PCa patients.

Clinical features	TMA				TCGA
	Case	Low, n (%)	High, n (%)	P	Case	Low, n (%)	High, n (%)	P
Tissue
Cancer	70	31 (44.29)	39 (55.71)	0.734	427	213 (49.88)	214 (50.12)	–
Non-cancer	10	5 (50.00)	5 (50.00)	–	0	–	–	–
Age (years)
≤60	14	7 (50.00)	7 (50.00)	0.679	190	84 (44.21)	106 (55.79)	0.036 *
>60	66	29 (43.94)	37 (56.06)	–	237	129 (54.43)	108 (45.57)	–
Gleason score
≤8	46	21 (45.65)	25 (54.35)	0.750	300	150 (50.00)	150 (50.00)	0.941
>8	24	10 (41.67)	14 (58.33)	–	127	63 (49.61)	64 (50.39)	–
Serum PSA levels (ng/ml)
≤2	–	–	–	–	378	190 (50.26)	188 (49.74)	0.245
>2	–	–	–	–	35	14 (40.00)	21 (60.00)	–
Pathological grade
pT1-pT2	4	2 (50.00)	2 (50.00)	0.834	–	–	–	–
pT3	65	29 (44.62)	36 (55.38)	–	–	–	–	–
Tumor stage
T1	0	–	–	-	153	81 (52.94)	72 (47.06)	0.249
T2	42	17 (40.48)	25 (59.52)	0.277	155	69 (44.52)	86 (55.48)	–
T3	14	8 (57.14)	6 (42.86)	–	48	27 (56.25)	21 (43.75)	–
T4	0	–	–	–	1	0 (0.00)	1 (100.00)	–
Lymph nodemetastasis
N0	56	25 (44.64)	31 (55.36)	–	303	147 (48.51)	156 (51.49)	0.450
N1	0	–	–	–	69	30 (43.48)	39 (56.52)	–
Distant metastasis
M0	56	25 (44.64)	31 (55.36)	–	401	196 (48.88)	205 (51.12)	0.539
M1	0	–	–	–	3	2 (66.67)	1 (33.33)	–

*means the difference is significant at the 0.05 level.